Posted by Michael Wonder on 03 Dec 2019
Cumberland Pharmaceuticals receives FDA approval for RediTrex product line
2 December 2019 - Cumberland Pharmaceuticals today announced that it has received approval from the U.S. FDA for RediTrex, its new line of methotrexate products.
RediTrex (methotrexate) injection is designed for the treatment of adult and paediatric patients with rheumatoid arthritis, as well as adults with psoriasis.
The approval of the product came after a number of communications with the FDA and several amendments to the new drug application we submitted to the FDA in late 2018.
